Soria JC - Search Results

1

Rationale for anti-OX40 cancer immunotherapy.

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Among authors: soria jc. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.

2

Use of angiogenesis inhibitors in tumour treatment.

Fayette J, Soria JC, Armand JP. Fayette J, et al. Among authors: soria jc. Eur J Cancer. 2005 May;41(8):1109-16. doi: 10.1016/j.ejca.2005.02.017. Eur J Cancer. 2005. PMID: 15911233 Review.

3

Molecularly targeted agents: their promise as cancer chemopreventive interventions.

Thiery-Vuillemin A, Nguyen T, Pivot X, Spano JP, Dufresnne A, Soria JC. Thiery-Vuillemin A, et al. Among authors: soria jc. Eur J Cancer. 2005 Sep;41(13):2003-15. doi: 10.1016/j.ejca.2005.06.005. Eur J Cancer. 2005. PMID: 16098739 Review.

4

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

Faivre S, Delbaldo C, Boige V, Pautier P, Soria JC, Namouni F, Peck R, Cohen M, Raymond E. Faivre S, et al. Among authors: soria jc. Eur J Cancer. 2008 Mar;44(5):674-82. doi: 10.1016/j.ejca.2008.01.016. Epub 2008 Mar 4. Eur J Cancer. 2008. PMID: 18308561 Clinical Trial.

5

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

Magné N, Chargari C, Castadot P, Ghalibafian M, Soria JC, Haie-Meder C, Bourhis J, Deutsch E. Magné N, et al. Among authors: soria jc. Eur J Cancer. 2008 Oct;44(15):2133-43. doi: 10.1016/j.ejca.2008.06.029. Epub 2008 Aug 7. Eur J Cancer. 2008. PMID: 18692389 Review.

6

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP. Soria JC, et al. Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21. Eur J Cancer. 2009. PMID: 19541476 Clinical Trial.

7

Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Viaud S, et al. Among authors: soria jc. Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9. Cancer Res. 2011. PMID: 21148486 Clinical Trial.

8

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N. Zoubir M, et al. Among authors: soria jc. Cell Cycle. 2011 Jan 1;10(1):118-26. doi: 10.4161/cc.10.1.14445. Epub 2011 Jan 1. Cell Cycle. 2011. PMID: 21200142 Clinical Trial.

9

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X. Postel-Vinay S, et al. Among authors: soria jc. J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444876

10

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC. Ferté C, et al. Among authors: soria jc. Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12. Eur J Cancer. 2011. PMID: 21489779 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

733 results

Search Page